GW Pharmaceuticals PLC Date and Time Change for Q4 and FY 2015 Results (3899H)
November 30 2015 - 7:00AM
UK Regulatory
TIDMGWP
RNS Number : 3899H
GW Pharmaceuticals PLC
30 November 2015
GW Pharmaceuticals Announces Date and Time Change for Q4 and
Year-End 2015 Financial Results and Conference Call
-Change to after market on 7 December to facilitate inclusion of
additional Epidiolex data-
London, UK, 30 Nov 2015: GW Pharmaceuticals plc (Nasdaq: GWPH,
AIM: GWP, "GW" or "the Company"), a biopharmaceutical company
focused on discovering, developing and commercializing novel
therapeutics from its proprietary cannabinoid product platform,
announces that it has changed the date and time for the release of
its fourth quarter and year-end results and associated conference
call to facilitate inclusion of newly available data from the
physician-led Epidiolex(R) expanded access program.
The new date and time for GW's fourth quarter and year-end
financial results for the period ending 30 September will be Monday
7 December, 2015 at 4:00 p.m. EST (9:00 p.m. GMT).
GW will also host a conference call the same day at 4:30 p.m.
EST (9:30 p.m. GMT). Conference call information will be provided
in the financial results press release issued after the U.S. market
close that day. A replay of the call will also be available through
the Company's website (www.gwpharm.com) shortly after the call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R) , which is approved for
the treatment of spasticity due to multiple sclerosis in 27
countries outside the United States. GW is advancing an orphan drug
program in the field of childhood epilepsy with a focus on
Epidiolex(R) , which is in Phase 3 clinical development for the
treatment of Dravet syndrome and Lennox-Gastaut syndrome and which
is also expected to enter Phase 3 clinical trials in the treatment
of Tuberous Sclerosis Complex. GW has a deep pipeline of additional
cannabinoid product candidates which includes Sativex in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer, as well as compounds in Phase 1 and 2 trials
for glioma, type 2 diabetes, and schizophrenia. For further
information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Stephen Schultz, VP Investor 917 280 2424 / 401 500
Relations (U.S.) 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway + 44 20 3727 1000
Peel Hunt LLP (UK NOMAD)
James Steel +44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLBLFXEFFLFBK
(END) Dow Jones Newswires
November 30, 2015 08:00 ET (13:00 GMT)
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024